Vasculitis & polymyalgia rheumatica
The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 giant cell arteritis (GCA) patients
Authors' conclusion
Regarding demographics, clinical manifestations and diagnostics, our study showed a similar composition compared to other studies. However, our data differed in terms of treatment regimens.
Study context
- Population
- GCA patients in the GeVas registry, German-speaking countries; 15 centres64% female
- Participants
- 195 patients
- Outcome
- Remission
Methodological detailssubgroup analysis, web-based, Recruitment started June 2019; 15 centres initiated by April 2023
- Subgroup analysis
- Web-based
- Recruitment started June 2019; 15 centres initiated by April 2023
Main finding
As reported in the abstract
Remission at 3 months
62%
Remission at 1 year
91%
Observational data: associations, not effects.
Further findings
Baseline characteristics · first assessment
- Age, average (IQR=69-82), years
- 76
- Newly diagnosed GCA
- 79%
- Included because of relapse
- 21%
- General symptoms
- 89%
- Ocular symptoms
- 31%
- Cranial symptoms
- 78%
Immunosuppressive treatment at start (all patients)
- Prednisolone
- 95%
- CYC
- 16%
- MTX
- 20%
- Tocilizumab
- 48%
Original publication
The Joint Vasculitis Registry in German-speaking countries (GeVas): subgroup analysis of 195 GCA patients. Clin Exp Rheumatol. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →